163 related articles for article (PubMed ID: 1625201)
1. Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes.
Wu EY; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1992 Jul; 262(1):225-30. PubMed ID: 1625201
[TBL] [Abstract][Full Text] [Related]
2. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes.
Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW
Glia; 1992; 5(1):48-55. PubMed ID: 1311704
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
Di Monte DA; Wu EY; Delanney LE; Irwin I; Langston JW
J Pharmacol Exp Ther; 1992 Apr; 261(1):44-9. PubMed ID: 1560384
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.
Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW
J Pharmacol Exp Ther; 1991 Aug; 258(2):594-600. PubMed ID: 1907660
[TBL] [Abstract][Full Text] [Related]
5. Differences in the disposition and toxicity of 1-methyl-4-phenylpyridinium in cultured rat and mouse astrocytes.
Tsai MJ; Lee EH
Glia; 1994 Dec; 12(4):329-35. PubMed ID: 7890335
[TBL] [Abstract][Full Text] [Related]
6. Impaired glutamate clearance as a consequence of energy failure caused by MPP(+) in astrocytic cultures.
Di Monte DA; Tokar I; Langston JW
Toxicol Appl Pharmacol; 1999 Aug; 158(3):296-302. PubMed ID: 10438663
[TBL] [Abstract][Full Text] [Related]
7. Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes.
Di Monte D; Ekström G; Shinka T; Smith MT; Trevor AJ; Castagnoli N
Chem Biol Interact; 1987; 62(2):105-16. PubMed ID: 3496169
[TBL] [Abstract][Full Text] [Related]
8. Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone.
Yoshihara S; Ohta S
Arch Biochem Biophys; 1998 Dec; 360(1):93-8. PubMed ID: 9826433
[TBL] [Abstract][Full Text] [Related]
9. Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+.
Schildknecht S; Pape R; Meiser J; Karreman C; Strittmatter T; Odermatt M; Cirri E; Friemel A; Ringwald M; Pasquarelli N; Ferger B; Brunner T; Marx A; Möller HM; Hiller K; Leist M
Antioxid Redox Signal; 2015 Nov; 23(13):1001-16. PubMed ID: 26413876
[TBL] [Abstract][Full Text] [Related]
10. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
11. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures.
Di Monte DA; Schipper HM; Hetts S; Langston JW
Glia; 1995 Oct; 15(2):203-6. PubMed ID: 8567072
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.
Kindt MV; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1987 Sep; 242(3):858-63. PubMed ID: 3498818
[TBL] [Abstract][Full Text] [Related]
13. 1-Methyl-4-phenyl-2,3-dihydropyridinium is transformed by ubiquinone to the selective nigrostriatal toxin 1-methyl-4-phenylpyridinium.
Shi H; Noguchi N; Xu Y; Niki E
FEBS Lett; 1999 Nov; 461(3):196-200. PubMed ID: 10567696
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease.
Lim KM; Kim HH; Bae ON; Noh JY; Kim KY; Kim SH; Chung SM; Shin S; Kim HY; Chung JH
Platelets; 2009 May; 20(3):163-70. PubMed ID: 19437333
[TBL] [Abstract][Full Text] [Related]
15. A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function.
Walker MJ; Jenner P; Marsden CD
Biochem Pharmacol; 1991 Jul; 42(4):913-9. PubMed ID: 1651082
[TBL] [Abstract][Full Text] [Related]
16. Impaired mutagenic activities of MPDP(+) (1-methyl-4-phenyl-2,3-dihydropyridinium) and MPP(+) (1-methyl-4-phenylpyridinium) due to their interactions with methylxanthines.
Ulanowska K; Piosik J; Gwizdek-Wiśniewska A; Wegrzyn G
Bioorg Med Chem; 2007 Aug; 15(15):5150-7. PubMed ID: 17533133
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical and toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridine to rat serotonin neurons in dissociated cell cultures.
Friedman LK; Mytilineou C
J Pharmacol Exp Ther; 1990 May; 253(2):892-8. PubMed ID: 2338661
[TBL] [Abstract][Full Text] [Related]
18. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
Riachi NJ; Harik SI; Kalaria RN; Sayre LM
J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures.
Reinhard JF; Carmichael SW; Daniels AJ
J Neurochem; 1990 Jul; 55(1):311-20. PubMed ID: 1972391
[TBL] [Abstract][Full Text] [Related]
20. Comparative toxicity and antioxidant activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes.
Ekström G; Di Monte D; Sandy MS; Smith MT
Arch Biochem Biophys; 1987 May; 255(1):14-8. PubMed ID: 3496045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
